Viatris Inc (VTRS) News

~bought some 3/15 $16 calls @.04 ahead of earnings tomorrow

VTRS new 52=week high

Pfizer Inc came out with Lyrica
Pregabalin (Lyrica) is a medication that treats nerve pain by calming overactive nerves.
It can also treat epilepsy.
Pfizer transferred Lyrica to Viastris Inc
Here is promising Drug Company for Epilepsy
$RSPI .0013
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients

Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/35041859/

https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/

The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X

VTRS reports 4Q22 results—issues 2023 guidance:

https://www.prnewswire.com/news-releases/viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-financial-guidance-301756171.html

Nothing that's been publicly disclosed.

VTRS names new CEO:

https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html

Scott Smith was already a VTRS director and was formerly the COO of Celgene.

VTRS anything going on? Related to RVNC? eom

VTRS anything going on? Related to RVNC? eom

VIATRIS - FDA APPROVES GENERIC FORM OF SYMBICORT

CLICK FOR FDA LINK


FDA Approves First Generic of Symbicort to Treat Asthma and COPD

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines


For Immediate Release:
March 15, 2022

Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks.

“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D., director of the Office of Generic Drugs in the FDA Center for Drug Evaluation and Research. “This reflects the FDA’s continued efforts to increase competition and access to quality, safe, effective and affordable medicines for patients and consumers.”

Asthma impacts 25 million people, more than five million of whom are children, while COPD afflicts more than 16 million, according to the National Heart, Lung, and Blood Institute. Asthma is a chronic, long-term condition that affects the airways in the lungs, which can be worsened by physical activity and most often starts during childhood. It can cause wheezing (a whistling sound when breathing), shortness of breath, and coughing. COPD, which includes emphysema and chronic bronchitis, is a long-term, chronic disease that causes airflow blockage and makes it difficult to breathe.

This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing). Two inhalations, two times a day (usually morning and night, about 12 hours apart), treat both diseases by preventing symptoms, such as wheezing for those with asthma, and by helping with better breathing, for those with COPD. The inhaler is approved for two strengths (160/4.5 mcg/actuation and 80/4.5 mcg/actuation).

The most common side effects associated with budesonide and formoterol fumarate dihydrate oral inhalation aerosol for those with asthma are nasopharyngitis (swelling of nasal passages and back of throat), headache, upper respiratory tract infection, pharyngolaryngeal (nose and mouth) pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis (thrush). For those with COPD, the most common side effects are nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.

The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device. To further facilitate generic drug development, and to assist the generic pharmaceutical industry in this process, the FDA publishes product-specific guidances (PSGs) describing the agency’s current thinking and expectations on how to develop generic drug products that are therapeutically equivalent to their brand name counterparts. In June 2015, FDA published a PSG for budesonide and formoterol fumarate dihydrate inhalation aerosol.

The FDA requires sponsors to submit appropriate data and information to demonstrate that complex generic drug-device combination products meet the agency’s rigorous approval standards. These standards ensure that generic drug products are as safe and effective as their brand name equivalents and meet the same high quality standards.

Complex products are medical products where uncertainty concerning the approval pathway or possible alternative approaches to product development can benefit from early scientific engagement, such as products with complex active ingredients and drug-device combination products.

Since drug-device combination products can be more challenging to develop, fewer exist, resulting in less market competition. Addressing the challenges related to complex generics, and promoting more generic competition to these medicines, is a key part of the FDA’s Drug Competition Action Plan, and the agency’s efforts to promote patient access and more affordable medicines.

The FDA granted approval of this generic budesonide and formoterol fumarate dihydrate inhalation aerosol to Mylan Pharmaceuticals, Inc.



The TE

VTRS sells JV stake in Humira/Enbrel/Eylea-biosimilars portfolio_to Biocon for $3B plus contingencies…

4Q21 results:
https://investor.viatris.com/news-releases/news-release-details/viatris-reports-strong-fourth-quarter-and-full-year-2021

CC slides:
https://investor.viatris.com/static-files/6a055dc2-4cd2-4d6c-91c9-c426ec1dcbce

Note: VTRS is retaining its participation in the Botox-biosimilar program with RVNC.

FDA approves VTRS’ generic Restasis—the first US generic for that brand:

https://www.prnewswire.com/news-releases/fda-approves-first-generic-of-restasis-301474142.html

sees u r right, good sign

This one should be trading over $15.00, some very corrupted MM's and the same manipulation coming from hedge funds going on, to keep it down, going into their earnings call and company big updates, there could be a run up that knocks all of the corrupted MM and henge fund trash onto their naked shorting butts in Jan going into Feb.

Fed.Cir. holds certain SNY patents, involving Lantus insulin pen, invalid in infringement suit against VTRS, per Bloomberg news.

Shorts are getting closer and closer to getting blown out and their butts handed to them, they better stop stacking on the offer the Jan 21 $15.00 calls, the dumbasses are going to end up having to buy them back higher.

Viatris (VTRS) “could combine biosimilars with Biocon and keep the optionality on IPO - doesn’t have to decide now.” the analyst wrote, adding $4 per share estimated for biosimilar business to indicate over $20 per share value for the company.

He probably would do that if you subscribe to his bashbag service, and even use whip cream for his own enjoyment.

Clay eat my sack

Viatris Inc. Announces Inaugural Quarterly Dividend

Board of Directors declared a quarterly dividend of eleven cents ($0.11) for each issued and outstanding share of the company's common stock. The dividend is payable on June 26, 2021 to stockholders of record at the close of business on May 24, 2021.

* * $VTRS Video Chart 05-10-2021 * *

Link to Video - click here to watch the technical chart video

hm, I bought in at 43 or so, don't know whats the real prob with it

$13 seems like a great buy-in price for a long hold. Dividend coming and should only be up from here.

Viatris CEO Heather Bresch is the daughter of West Virginia Senator Joe Manchin. More powerful connections for Doc?

Excellent VTRS swing so far...

Nice rebound as expected! So long as we don't get a major market correction (which we could any day), I expect this will be a great long hold.

Yep, I'm having a hard time keeping up w/ the whipsaw call/put action.

Sorry, meant 2Million (not billion)

Looks like 2B shares were added today, driving price down a bit. Once those are all bought up, price will rise back up. Good day to buy IMO.

It's looking good the past few days, even with the delay:

https://www.biocon.com/biocon-biologics-statement-on-the-status-of-bevacizumab-fda-action-date-in-dec-2020/

VTRS.... the only good thing
that came out of owning PFE stock ;)

Run Forrest, Run!

Opened a long straddle today. Go VTRS, move!

$VTRS moving higher, chart gaining momo as it moves towards 20

Old news, chart indicates heading higher towards 20-25 within 3-4 months

Vitaris, Pfizer announced that it would merge its off-patent branded and generic established medicines business, known as Upjohn, with Mylan. The transaction created a new company, Viatris, using a reverse Morris trust structure.[80][third-party source needed] The new business will trade on the NASDAQ stock exchange under the ticker NASDAQ: VTRS.[80] Pfizer shareholders would own 57% of the new combined business. The Board of Viatris will be composed of Robert J. Coury as Executive Chairman (currently Executive Chairman of Mylan), Michael Goettler as CEO (currently Global President of Upjohn), eight people chosen by Mylan and three chosen by Pfizer. In December 2019, Pfizer chose former CEO and Chairman, Ian Read and current Director of Pfizer, James Kilts. In February 2020 Pfizer announced W. Don Cornwell and their final Board selection with Mylan selecting JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish and Pauline van der Meer Mohr as their Board nominees – all current directors of Mylan.[80]

In October 2020, the US Federal Trade Commission approved the combination.[81]

Viatris (VTRS)

$VTSR moving in right direction..

Chart gaining strength. Next stop 21.00ps

$VTRS gaining notice by the hedge funds! Looking vg here

Looking to move much higher!

I’m not going anywhere and will hold. It will take a few months for The Street to start pounding the table. 12 month target 25-30

Viatris Inc. (VTRS) investors to reap big returns again




https://marketingsentinel.com/2020/12/01/viatris-inc-vtrs-investors-to-reap-big-returns-again/

Pfizer investors can look forward to a burst of growth ahead. In November, Lyrica and the rest of the company's post-exclusivity brands merged with Mylan to form a new company called Viatris (NASDAQ: VTRS).


Viatris (VTRS)

IF PFE is up then VTRS is going to be down my observance only!

IF PFE is up then VTRS is going to be down my observance only!

Cranmer pumping 500.00 stocks had no clue abt vtrs. Shameful mad money is still on

Great news! https://finance.yahoo.com/news/viatris-inc-announces-fda-tentative-203400409.html

Maybe distribute the vaccine for
Covid?

VTRS will most definitely flourish. Generic business aside management seems quite aggressive and poised for much larger growth. Hold onto your shrs and don’t be fooled. This is a global play and will fuel its growth much further.

Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs
Combination of Mylan and Pfizer's Upjohn Business Focused on Access and Improved Patient Health and Investor Wealth.


PITTSBURGH, Nov. 16, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) launched today following the successful combination of Mylan N.V. and Pfizer's Upjohn business. By combining these two complementary legacy companies, Viatris has the scientific, manufacturing and distribution expertise with proven regulatory, medical and global commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories.



https://newsroom.viatris.com/2020-11-16-Viatris-Inc-Launches-as-a-New-Kind-of-Healthcare-Company-Positioned-to-Meet-the-Worlds-Evolving-Healthcare-Needs

Viatris (VTRS)

Who will be Amazons med distribution company?